Literature DB >> 21134897

Cerebrospinal fluid M staging for medulloblastoma: reappraisal of Chang's M staging based on the CSF flow.

Ji Hoon Phi1, Joongyub Lee, Kyu-Chang Wang, Byung-Kyu Cho, In-One Kim, Chul-Kee Park, Chae-Yong Kim, Hyo Seop Ahn, Il Han Kim, Seung-Ki Kim.   

Abstract

Tumor seeding is a strong negative prognostic factor for patients with medulloblastoma. Because Chang's M staging is based primarily on CT and myelographic findings and might be contradictory to the direction of normal cerebrospinal fluid (CSF) flow, seeding patterns and appropriate staging of medulloblastoma need to be revisited in patients diagnosed in the MRI era. We retrospectively reviewed the clinical and radiological data of 86 patients with a diagnosis of medulloblastoma who were treated in the MRI era. The presence of seeding in each subarachnoid space compartment and the patterns of seeding were analyzed in correlation with patient survival data. Thirty-four patients had gross seeding on perioperative MRI. Thirty-two patients had seeding in the spinal compartment. Sixteen and 12 patients had seeding in the infratentorial and supratentorial compartments, respectively. There was an apparent hierarchy of seeding (ie, from seeding in the spinal compartment up to the supratentorial compartment). Patients with seeding in the spinal compartment had longer progression-free survival (P = .038) and a tendency toward better overall survival (P = .053) compared with patients with seeding in intracranial compartments. We modified Chang's M staging based on the CSF flow and termed this approach "CSF M staging." CSF M staging for medulloblastoma, in which intracranial seeding occupies a higher rank than spinal seeding, was a better predictor of patient prognosis. This modified staging method may be applied to metastatic staging of brain tumors located in the fourth ventricle.

Entities:  

Mesh:

Year:  2010        PMID: 21134897      PMCID: PMC3064600          DOI: 10.1093/neuonc/noq171

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  25 in total

1.  Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study.

Authors:  Charles G Eberhart; James L Kepner; Patricia T Goldthwaite; Larry E Kun; Patricia K Duffner; Henry S Friedman; Douglas R Strother; Peter C Burger
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

2.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

Review 3.  Medulloblastoma: clinical and biologic aspects.

Authors:  R J Packer; P Cogen; G Vezina; L B Rorke
Journal:  Neuro Oncol       Date:  1999-07       Impact factor: 12.300

4.  The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: a phase III study in a high-risk patient population.

Authors:  M S Yao; M P Mehta; J M Boyett; H Li; B Donahue; L B Rorke; P M Zeltzer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-06-01       Impact factor: 7.038

5.  Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors.

Authors:  A Gajjar; M Fouladi; A W Walter; S J Thompson; D A Reardon; T E Merchant; J J Jenkins; A Liu; J M Boyett; L E Kun; R L Heideman
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

6.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

Authors:  P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

7.  Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945.

Authors:  Maryam Fouladi; Daniel L Hunt; Ian F Pollack; Gregor Dueckers; Peter C Burger; Laurence E Becker; Allen J Yates; Floyd H Gilles; Richard L Davis; James M Boyett; Jonathan L Finlay
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

8.  A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).

Authors:  Jeffrey Allen; Bernadine Donahue; Minesh Mehta; Douglas C Miller; Lucy B Rorke; Regina Jakacki; Patricia Robertson; Richard Sposto; Emi Holmes; Gilbert Vezina; Karin Muraszko; Diane Puccetti; Michael Prados; Ka-Wah Chan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-07       Impact factor: 7.038

9.  Large-cell medulloblastomas. A distinct variant with highly aggressive behavior.

Authors:  F Giangaspero; L Rigobello; M Badiali; M Loda; L Andreini; G Basso; F Zorzi; A Montaldi
Journal:  Am J Surg Pathol       Date:  1992-07       Impact factor: 6.394

Review 10.  Anatomy, biology and concepts, pertaining to lung cancer stage classification.

Authors:  Frank C Detterbeck; Lynn T Tanoue; Daniel J Boffa
Journal:  J Thorac Oncol       Date:  2009-04       Impact factor: 15.609

View more
  9 in total

1.  Differential imaging characteristics and dissemination potential of pilomyxoid astrocytomas versus pilocytic astrocytomas.

Authors:  Bálint Alkonyi; Johannes Nowak; Astrid K Gnekow; Torsten Pietsch; Monika Warmuth-Metz
Journal:  Neuroradiology       Date:  2015-02-10       Impact factor: 2.804

2.  Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.

Authors:  Ae Kyung Park; Seung-Jun Lee; Ji Hoon Phi; Kyu-Chang Wang; Dong Gyu Kim; Byung-Kyu Cho; Christine Haberler; Sarah Fattet; Christelle Dufour; Stéphanie Puget; Christian Sainte-Rose; Franck Bourdeaut; Jacques Grill; Olivier Delattre; Seung-Ki Kim; Woong-Yang Park
Journal:  Neuro Oncol       Date:  2011-11-16       Impact factor: 12.300

3.  Tumors in the cerebellopontine angle in children: warning of a high probability of malignancy.

Authors:  Ji Hoon Phi; Kyu-Chang Wang; In-One Kim; Jung-Eun Cheon; Jung Won Choi; Byung-Kyu Cho; Seung-Ki Kim
Journal:  J Neurooncol       Date:  2013-02-13       Impact factor: 4.130

4.  In vivo bioluminescence imaging for leptomeningeal dissemination of medulloblastoma in mouse models.

Authors:  Seung Ah Choi; Pil Ae Kwak; Seung-Ki Kim; Sung-Hye Park; Ji Yeoun Lee; Kyu-Chang Wang; Hyun Jeong Oh; Kyuwan Kim; Dong Soo Lee; Do Won Hwang; Ji Hoon Phi
Journal:  BMC Cancer       Date:  2016-09-08       Impact factor: 4.430

5.  Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model.

Authors:  Ji Hoon Phi; Seung Ah Choi; Pil Ae Kwak; Ji Yeoun Lee; Kyu-Chang Wang; Do Won Hwang; Seung-Ki Kim
Journal:  Oncotarget       Date:  2017-05-24

6.  Etoposide-Bound Magnetic Nanoparticles Designed for Remote Targeting of Cancer Cells Disseminated Within Cerebrospinal Fluid Pathways.

Authors:  Herbert H Engelhard; Alexander J Willis; Syed I Hussain; Georgia Papavasiliou; David J Banner; Amanda Kwasnicki; Sajani S Lakka; Sangyeul Hwang; Tolou Shokuhfar; Sean C Morris; Bing Liu
Journal:  Front Neurol       Date:  2020-11-27       Impact factor: 4.003

7.  ID3 contributes to cerebrospinal fluid seeding and poor prognosis in medulloblastoma.

Authors:  Ji Hoon Phi; Seung Ah Choi; Sang-Hee Lim; Joongyub Lee; Kyu-Chang Wang; Sung-Hye Park; Seung-Ki Kim
Journal:  BMC Cancer       Date:  2013-06-15       Impact factor: 4.430

8.  miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47.

Authors:  Seung Yeob Yang; Seung Ah Choi; Ji Yeoun Lee; Ae-Kyung Park; Kyu-Chang Wang; Ji Hoon Phi; Eun Jung Koh; Woong-Yang Park; Sung-Hye Park; Do Won Hwang; Hee Won Jung; Seung-Ki Kim
Journal:  Oncotarget       Date:  2015-12-22

9.  Intra-operative cerebrospinal fluid sampling versus post-operative lumbar puncture for detection of leptomeningeal disease in malignant paediatric brain tumours.

Authors:  Sharon Y Y Low; Chen Min Wei; Kenneth T E Chang; Chan Yiong Huak; Ng Lee Ping; Seow Wan Tew; David C Y Low
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.